Ken Griffin Crispr Therapeutics Ag Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $4.06 Million - $5.71 Million	-91,000 Reduced 24.53%	280,000 $13.2 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $5.85 Million - $7.8 Million	-114,400 Reduced 23.57%	371,000 $20 Million
Q1 2024 May 15, 2024	SELL	$60.67 - $89.12 $13 Million - $19.1 Million	-214,300 Reduced 30.63%	485,400 $33.1 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $11.9 Million - $22.3 Million	309,200 Added 79.18%	699,700 $43.8 Million
Q3 2023 Nov 14, 2023	BUY	$45.39 - $59.0 $2.29 Million - $2.98 Million	50,500 Added 14.85%	390,500 $17.7 Million
Q2 2023 Aug 14, 2023	BUY	$43.47 - $67.77 $3.43 Million - $5.35 Million	78,900 Added 30.22%	340,000 $19.1 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $6.22 Million - $8.51 Million	-151,600 Reduced 36.73%	261,100 $11.8 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $18.7 Million - $31.4 Million	-477,500 Reduced 53.64%	412,700 $16.8 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $727,090 - $996,982	11,900 Added 1.35%	890,200 $58.2 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.2B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.